Intellia Therapeutics: Peers

The FY2025 (Dec) proxy of Intellia Therapeutics names 20 peer companies for pay. Among Intellia Therapeutics and these peers, CEO pay was 9th highest of 11 and total shareholder return was 10th highest of 11.

9th highest of 11in Intellia Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:

$4.6M$19.2M

10th highest of 11in Intellia Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:

$15$524

Pay peer group, FY2025 (Dec) proxy

Madrigal Pharmaceuticals
BridgeBio Pharma
ImmunityBio
Immunovant
IDEAYA Biosciences
Vir Biotechnology
CRISPR Therapeutics AG
Beam Therapeutics
Denali Therapeutics
Relay Therapeutics
Allogene Therapeutics, Inc.Not disclosedNot disclosed
Arrowhead PharmaceuticalsNot disclosedNot disclosed
Editas Medicine, Inc.Not disclosedNot disclosed
Iovance BiotherapeuticsNot disclosedNot disclosed
Prime Medicine, Inc.Not disclosedNot disclosed
Rocket Pharmaceuticals, Inc.Not disclosedNot disclosed
Sana Biotechnology, Inc.Not disclosedNot disclosed
VaxcyteNot disclosedNot disclosed
Verve Therapeutics, Inc.Not disclosedNot disclosed
XencorNot disclosedNot disclosed
20 companies

Changes by year

No proxy on file names a change to the peer group.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.